Skip to ContentSkip to Navigation
Practical matters How to find us dr. ir. M.H. (Maaike) Oosterveer


Increased atherosclerosis in a mouse model of glycogen storage disease type 1a

A retrospective in-depth analysis of continuous glucose monitoring datasets for patients with hepatic glycogen storage disease: Recommended outcome parameters for glucose management

Disrupted glucose-6-phosphate-ChREBP signalling aggravates hepatomegaly and accelerates liver disease progression in a mouse model for Glycogen Storage Disease type 1a

Enantiomer-specific pharmacokinetics of D,L-3-hydroxybutyrate: Implications for the treatment of multiple acyl-CoA dehydrogenase deficiency

Hepatocyte-specific glucose-6-phosphatase deficiency disturbs platelet aggregation and decreases blood monocytes upon fasting-induced hypoglycemia

Impaired Very-Low-Density Lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia

Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR-associated protein 9-Mediated Gene Editing

Exploiting epigenetics for the treatment of inborn errors of metabolism

Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels

Macrophage NCOR1 protects from atherosclerosis by repressing a pro-atherogenic PPARĪ³ signature

Read more


Academic carreer

Animal Testing